InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway

InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development

Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC

KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer

Prokaryotics and Basilea team up to tackle deadly fungal infections

The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections

Shilpa Medicare aims for US approval of chemo nausea drug

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections

BeOne Medicines wins first-in-world nod for Sonrotoclax in China

The approval is backed by data showing deep, durable responses and manageable tolerability

Granules Pharmaceuticals secures FDA tentative approval and 180-day exclusivity for Generic Dyanavel XR

This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million

GSK reports breakthrough results in chronic hepatitis B trials

Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy

The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases

Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer

The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2

Newron secures key European patent for schizophrenia drug Evenamide

This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately